Azafaros' Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

          Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolledTopline data from the study, exp...

Related Keywords

Brazil ,United Kingdom ,Netherlands ,Curitiba ,Paranár ,United States ,Switzerland ,Dutch ,Swiss ,Porto Alegre ,Roberto Giugliani ,Leiden University ,European Medicines Agency ,Drug Administration ,Healthcare Products Regulatory Agency ,Genetics Service ,Azafaro Phase ,Medical Genetics Service ,Hospital Clinicas De Porto Alegre ,Lead Principal Investigator ,Daniel Almeida ,Stefano Portolano ,Rare Pediatric Disease Designations ,United States Food ,Orphan Medicinal Product Designation ,Innovation Passport ,United Kingdom Medicines ,Fast Track Designation ,Orphan Drug Designations ,Tay Sachs Diseases ,Niemann Pick ,Biogeneration Ventures ,